Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Newron Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 11, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	363	174	88	28	29	38
Market Cap Growth	76.37%	97.16%	219.36%	-4.32%	-24.65%	-66.14%
Enterprise Value	372	209	118	44	34	23
Last Close Price	17.50	8.95	4.95	1.55	1.62	2.15
PE Ratio	15.74	11.72	-	-	-	-
Forward PE	-	10.63	-	7.84	-	-
PS Ratio	6.50	3.61	10.48	4.59	4.84	6.74
PB Ratio	245.87	127.32	-3.17	-1.99	8.98	2.06
P/TBV Ratio	246.03	127.32	-	-	8.98	2.06
EV/Sales Ratio	6.65	4.34	13.95	7.26	5.77	4.13
EV/EBITDA Ratio	11.26	8.52	-	-	-	-
EV/EBIT Ratio	11.32	8.53	-	-	-	-
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-
Net Debt / Equity Ratio	5.92	27.88	-1.20	-1.63	2.73	-0.28
Net Debt / EBITDA Ratio	0.27	1.55	-3.12	-1.72	-0.69	0.27
Net Debt / FCF Ratio	0.38	-2.31	-3.53	-2.06	-0.74	0.31
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%
Return on Invested Capital (ROIC)	263.58%	80.74%	-157.51%	-130.08%	-103.26%	-134.50%
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%
Earnings Yield	6.51%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%
FCF Yield	6.31%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.